Skip to main content

Table 1 Comparison of the groups with regard to histological, biochemical, and radiological study assessments

From: Epidermal growth factor or platelet-rich plasma combined with induced membrane technique in the treatment of segmental femur defects: an experimental study

 

Group 1 (PRP)

Group 2 (EGF)

Group 3 (controls)

p

Assessments at week 6 (mean ± SD)

 Histological CD31 assessment (counts/mm2)

143.7 ± 8.2

151.1 ± 9.2

125.2 ± 13.3

< 0.001

 Membrane TGF level (ng/mL)

246.4 ± 54.3

257.7 ± 55.2

141.8 ± 20.8

< 0.001

 Membrane VEGF level (pg/mL)

842.0 ± 98.5

754.8 ± 118.7

430.5 ± 92.2

< 0.001

Assessments at week 12 (mean ± SD)

 Histological CD31 assessment (counts/mm2)

137.3 ± 17.3

138.1 ± 14.0

99.6 ± 25.5

0.003

 Membrane TGF level (ng/mL)

397.4 ± 44.4

379.3 ± 63.3

326.4 ± 42.0

0.032

 Membrane VEGF level (pg/mL)

318.0 ± 95.2

273.0 ± 72.1

228.9 ± 44.9

0.086

 Bone VEGF level (pg/mL)

192.2 ± 6.7

198.1 ± 5.7

176.3 ± 7.2

0.003

 Bone BMP-2 level (pg/mL)

191.9 ± 8.4

237.6 ± 37.3

117.1 ± 43.0

0.012

Lane score (median, range)

    

 Anteroposterior

4 (3-4)

3 (2-4)

1 (1-2)

0.015

 Lateral

4 (2-4)

3.5 (2-4)

1 (1-2)

0.026

 CT

3 (2-4)

3 (2-3)

1 (1-2)

0.026

 3D

3.5 (2-4)

4 (3-4)

1.5 (1-3)

0.044

  1. Abbreviations: PRP platelet rich plasma, EGF epidermal growth factor, CD 31 cluster of differentiation 31, TGF-beta transforming growth factor-beta, BPM-2 bone morphogenetic protein 2, VEGF vascular endothelial growth factor, CT computed tomography, 3D three-dimensional